1. Luxembourg Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Eurofins Scientific SE

Eurofins Scientific SE

ERFSF
Eurofins Scientific SEUS flagOther OTC
68.80
USD
-1.97
- -
12.02BMarket Cap
Eurofins Scientific SE
ERFSF
(Other OTC)

Recent

price

68.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.78
5.79
7.16
8.17
9.32
12.75
15.86
17.38
21.36
25.63
29.21
35.08
34.87
33.77
36.47
40.58
5.79
Revenue per Share
0.18
0.39
0.45
0.48
0.52
0.57
1.09
1.27
1.26
1.1
2.9
4.09
3.17
1.61
2.13
2.64
0.4
Basic EPS, GAAP
0.31
0.39
0.43
0.47
0.51
0.8
1.08
0.93
1.01
2
4.66
5.25
2.47
2.43
4.15
3.14
0.39
Free Cash Flow per Basic Share
0.01
0.02
0.08
0.1
0.12
0.13
0.14
0.2
0.24
0.29
- -
0.68
1
0.99
0.5
0.6
- -
Dividend per Share
0.41
0.61
0.83
1.04
1.47
1.05
1.81
3.07
3.73
4.05
7.05
10.27
12.13
12.42
14.13
16.83
0.61
Book Value per Share
-0.32
-0.83
-0.68
-0.99
-1.38
-4.47
-1.32
-4.44
-9.28
-9.15
-3.4
-1.74
-3.08
-1.09
-1.28
-4.28
-0.83
Tangible Book Value per Share
142
143
146
150
151
153
160
171
177
178
186
192
192
193
191
180
143
Basic Weighted Avg Shares
680
829
1,044
1,226
1,410
1,950
2,537
2,971
3,781
4,563
5,439
6,718
6,712
6,515
6,951
7,296
829
Sales/Revenue/Turnover
7.32
11.25
9.58
9.1
9.45
10.51
11.03
9.67
8.9
7.04
14.81
18.98
11.67
8.39
10.45
11.22
10.95
Operating Margin (%)
42
48
55
67
81
111
142
176
224
396
426
451
504
565
597
630
48
Depreciation Expense
25
55
66
72
79
87
174
217
224
195
539
783
610
310
406
475
57
Net Income, GAAP
29.95
19.61
21.77
19.28
21.91
31.91
26.83
12.5
22.88
28.1
22.16
25.89
22.33
27.29
26.88
27.69
19.61
Effective Tax Rate (%)
3.73
6.68
6.31
5.89
5.61
4.48
6.86
7.3
5.92
4.28
9.92
11.65
9.09
4.76
5.85
6.51
6.83
Profit Margin (%)
87
159
116
306
170
649
869
375
255
22
822
463
541
945
342
224
159
Working Capital
239
401
383
667
638
1,497
1,340
1,662
2,766
3,087
2,917
2,500
3,112
3,326
3,132
3,705
401
LT Debt
231
320
372
395
664
1,080
1,757
2,482
2,722
2,898
3,716
4,677
4,851
5,137
5,385
4,577
320
Total Equity
7.23
11.01
8.86
8.47
7.66
6.23
6.46
6.05
4.64
3.54
8.83
12.28
7.3
4.37
5.56
6.2
10.71
Return on Invested Capital (%)
11.7
15.58
15.46
12.96
11.61
8.24
11.65
11.47
8.26
6.48
14.04
18.45
13.3
6.72
8.13
8.53
16.62
Return on Capital (%)
49.44
76.04
63.44
52.19
41.83
45.62
77.45
53.29
37.77
28.26
53.06
47.74
28.37
13.11
15.97
16.6
77.74
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'11
Sep'11
Dec'11
ST Debt
42
21
34
LT Borrowings
310
399
398
LT Finance Leases
- -
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
143
143
144
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'11
Sep'11
Dec'11
Total Current Assets
301
389
442
Cash, Cash Equivalents & STI
81
161
179
Accounts Receivable, Net
180
185
202
Inventories
9
9
10
Total Current Liabilities
213
201
283
Payables & Accruals
- -
- -
- -
ST Debt
42
21
34
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.35%
5.06%
-15.01%
Free Cash Flow
29.03%
0.35%
-28.64%
Net Income, GAAP
31.24%
4.35%
16.83%
Sales/Revenue/Turnover
14.65%
6.43%
4.96%
Total Cash Common Dividend
2,599.88%
5,197.94%
12.66%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,515
2024
- -
- -
- -
- -
6,951
2025
- -
- -
- -
- -
7,296

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.61
2024
- -
- -
- -
- -
2.13
2025
- -
- -
- -
- -
2.64

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.99
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.6
Similar Companies
Dirui Industrial Co.,Ltd. (300396.SZ)
Precipio, Inc. (PRPO)
Synlab AG (SYAB.DE)
StageZero Life Sciences Ltd. (SZLS.TO)
Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
Atlantic International Corp. (ATLN)
Business
Eurofins Scientific SE is a global leader in bio-analytical testing and laboratory services, offering comprehensive analytical solutions to the pharmaceutical, food, environmental, agriscience, consumer products, forensics, advanced material sciences, and clinical diagnostics industries. The company provides an extensive portfolio of over 200,000 validated analytical methods covering safety, identity, purity, composition, authenticity, origin, traceability, and quality assessments. Its core products and services include food testing; pharmaceutical and biopharmaceutical testing, encompassing bioanalytical, microbiology, and stability studies; environmental testing for air, water, and soil; consumer products testing, including cosmetics; genomics and specialized molecular clinical diagnostics; discovery pharmacology; forensic science services; and biopharma contract research and manufacturing services. Eurofins also delivers in-vitro diagnostic products and clinical diagnostic testing services globally. The group operates a decentralized and entrepreneurial network of over 950 laboratories in more than 60 countries, supported by a workforce of approximately 63,000 employees. Founded in 1987 and headquartered in Luxembourg, Eurofins has rapidly expanded through organic growth, strategic acquisitions, and ongoing innovation in biotechnology and analytical chemistry. Recent major company developments include the acquisition of SYNLAB's clinical diagnostics division in Spain in early 2025, significantly enhancing Eurofins' clinical diagnostics presence and capabilities in the Spanish market with an extensive network serving both public and private sectors. In 2024, Eurofins acquired Orchid Cellmark, a UK-based DNA and forensic testing company, and Infinity Laboratories, Inc., based in Colorado, expanding its biopharmaceutical and medical device testing network in the U.S. Eurofins also integrated advanced molecular testing services by acquiring Beacon Discovery, specializing in drug research, and DNA Diagnostics Centers to broaden its genetic testing services. The company continues to invest heavily in digitalization, automation, and state-of-the-art laboratory infrastructure to improve turnaround times and service quality. Eurofins launched Eurofins Sustainability Solutions in 2022, emphasizing its commitment to environmental and social governance through innovative analytical services. Eurofins Scientific SE generates diversified revenues from its business segments including food testing, pharmaceutical and biopharmaceutical testing, environmental analysis, consumer products testing, and clinical diagnostics. Its broad geographic footprint, advanced technological capabilities, and diversified portfolio position Eurofins as a key global provider of testing, inspection, certification, and contract research services tailored to regulatory compliance, product safety, and innovation across multiple high-growth industries. The company is publicly traded on the Euronext Paris Stock Exchange under the ticker ERF (ISIN FR0014000MR3).

Company News

APIChat